iRhythm Technologies Inc. (IRTC)

77.42
0.73 0.93
NASDAQ : Health Technology
Prev Close 78.15
Open 78.54
Day Low/High 73.15 / 78.55
52 Wk Low/High 58.99 / 98.37
Volume 204.13K
Avg Volume 474.90K
Exchange NASDAQ
Shares Outstanding 24.69M
Market Cap 1.97B
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

New Expert Statement Recognizes Patch Monitors Such As Zio By IRhythm As Effective For Atrial Fibrillation Monitoring Post-Ablation

Confirms Value of Extended Continuous Cardiac Monitoring in Symptomatic and Asymptomatic Post-Ablation Patients

IRTC Crosses Above Average Analyst Target

In recent trading, shares of iRhythm Technologies Inc have crossed above the average analyst 12-month target price of $37.75, changing hands for $38.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

New Study Confirms Extended Continuous Cardiac Monitoring Is More Efficient Than Holter Monitoring For Cryptogenic Stroke Patients

Data Presented at the European Stroke Organisation Conference Shows Zio® by iRhythm Cardiac Monitoring Shortens Time to Diagnosis After Cryptogenic Stroke

IRhythm Technologies Announces First Quarter 2017 Financial Results

Raises Guidance for Full Year 2017

iRhythm Technologies Reaches Analyst Target Price

In recent trading, shares of iRhythm Technologies Inc have crossed above the average analyst 12-month target price of $34.75, changing hands for $35.24/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Zio By IRhythm Gains Further Recognition As Key Diagnostic Cardiac Monitoring System By US And UK Health Organizations

Zio system becoming standard of care for diagnosis and management of arrhythmias; could be more efficient and accurate than legacy monitors in arrhythmia detection

IRTC Crosses Above Average Analyst Target

In recent trading, shares of iRhythm Technologies Inc have crossed above the average analyst 12-month target price of $34.75, changing hands for $34.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

The IRTC Paradox: Analysts Bullish But Forecast -7.31% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with iRhythm Technologies Inc . The average 12-month price target for IRTC — averaging the work of 4 analysts — reveals an average price target of $34.75/share.

The IRTC Paradox: Analysts Bullish But Forecast -10.84% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with iRhythm Technologies Inc . The average 12-month price target for IRTC — averaging the work of 4 analysts — reveals an average price target of $31.75/share.

iRhythm Technologies Reaches Analyst Target Price

iRhythm Technologies Reaches Analyst Target Price

In recent trading, shares of iRhythm Technologies Inc have crossed above the average analyst 12-month target price of $30.75, changing hands for $31.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

IRTC Crosses Above Average Analyst Target

IRTC Crosses Above Average Analyst Target

In recent trading, shares of have crossed above the average analyst 12-month target price of $30.25, changing hands for $30.49/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

IRhythm Technologies Announces New Study Suggests Extended Continuous Cardiac Monitoring Is More Useful Than Holter Monitoring For Adult Congenital Heart Disease Patients

IRhythm Technologies Announces New Study Suggests Extended Continuous Cardiac Monitoring Is More Useful Than Holter Monitoring For Adult Congenital Heart Disease Patients

Data Presented Today at American Heart Association Scientific Sessions Shows iRhythm Technologies' Zio® System Leads to More Definitive Arrhythmia Diagnosis

Why You Should Buy iRhythm Technologies' Stock Right Now

Why You Should Buy iRhythm Technologies' Stock Right Now

It's time to buy shares of iRhythm Technologies (IRTC), before the banks that underwrote its IPO begin issuing research reports on the stock.

TheStreet Quant Rating: D+ (Sell)